Search research articles
Contact Us
Filters
Showing results (81-90 of 94) with videos related to
Page
of 10
Sort By:
Diabetes, Obesity & Metabolism
|
December 22, 2005
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)
A J Garber, J Wahlen, T Wahl, et al.
The American Journal of Medicine
|
January 16, 1998
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial
A J Garber, T G Duncan, A M Goodman, et al.
Geriatrics
|
April 1, 1983
Managing cardiac disease in patients with diabetes mellitus
S R Mather, A J Garber, M Attar, et al.
Journal of Cyclic Nucleotide Research
|
January 1, 1981
[125I]iodopindolol: a new beta adrenergic receptor probe
E G Ezrailson, A J Garber, P J Munson, et al.
The Journal of Clinical Investigation
|
July 1, 1976
The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man
A J Garber, P E Cryer, J V Santiago, et al.
Diabetes, Obesity & Metabolism
|
April 13, 2013
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
A Philis-Tsimikas, S Del Prato, I Satman, et al.
Metabolism: Clinical and Experimental
|
December 1, 1980
The effect of diet upon carbohydrate metabolism, insulin resistance, and blood pressure in congenital total lipoatrophic diabetes
B S Keenan, R T Kirland, A J Garber, et al.
Diabetes, Obesity & Metabolism
|
February 21, 2008
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
A J Garber, J E Foley, M A Banerji, et al.
Advances in Cyclic Nucleotide Research
|
January 1, 1978
Sarcoplasmic reticulum: a potential internal cyclic AMP effector site and beta-adrenergic receptor
M L Entman, E P Bornet, W B Van Winkle, et al.
Diabetes, Obesity & Metabolism
|
November 26, 2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
J Jendle, M A Nauck, D R Matthews, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 94) with videos related to
Sort By:
Page
of 10
Diabetes, Obesity & Metabolism
|
December 22, 2005
Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study)
A J Garber, J Wahlen, T Wahl, et al.
The American Journal of Medicine
|
January 16, 1998
Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial
A J Garber, T G Duncan, A M Goodman, et al.
Geriatrics
|
April 1, 1983
Managing cardiac disease in patients with diabetes mellitus
S R Mather, A J Garber, M Attar, et al.
Journal of Cyclic Nucleotide Research
|
January 1, 1981
[125I]iodopindolol: a new beta adrenergic receptor probe
E G Ezrailson, A J Garber, P J Munson, et al.
The Journal of Clinical Investigation
|
July 1, 1976
The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man
A J Garber, P E Cryer, J V Santiago, et al.
Diabetes, Obesity & Metabolism
|
April 13, 2013
Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents
A Philis-Tsimikas, S Del Prato, I Satman, et al.
Metabolism: Clinical and Experimental
|
December 1, 1980
The effect of diet upon carbohydrate metabolism, insulin resistance, and blood pressure in congenital total lipoatrophic diabetes
B S Keenan, R T Kirland, A J Garber, et al.
Diabetes, Obesity & Metabolism
|
February 21, 2008
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
A J Garber, J E Foley, M A Banerji, et al.
Advances in Cyclic Nucleotide Research
|
January 1, 1978
Sarcoplasmic reticulum: a potential internal cyclic AMP effector site and beta-adrenergic receptor
M L Entman, E P Bornet, W B Van Winkle, et al.
Diabetes, Obesity & Metabolism
|
November 26, 2009
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
J Jendle, M A Nauck, D R Matthews, et al.
Page
of 10